ARK Investment Management, led by Cathie Wood, disclosed its trading records for October 15, continuing to add to artificial intelligence infrastructure and biotechnology companies while trimming positions in some large technology stocks.
ARK purchased approximately $18.96 million in Iambic Therapeutics shares, $15.82 million in Recursion Pharmaceuticals, Inc. shares, and $12.67 million in CoreWeave, Inc. shares. On the other side, it sold about $7.64 million in Amazon.com shares and reduced holdings in Shopify and Palantir Technologies Inc.
Major Buys: Adding to Biotechnology and AI Infrastructure Companies
Iambic Therapeutics (IAM): 1,184,955 shares, $18.9593 million
Recursion Pharmaceuticals (RXRX): 4,230,235 shares, $15.8211 million
CoreWeave (CRWV): 192,566 shares, $12.667 million
Rocket Lab (RKLB): 168,633 shares, $9.9797 million
Freenome (FRNM): 25,455 shares, $310,300
Among these, Iambic was the largest single buy of the day, with the transaction completed through the ARKG fund. The Recursion purchase was mainly executed through the ARKK fund. Notably, ARK added another 192,600 CoreWeave shares following its purchase on the previous trading day, continuing its allocation to AI computing infrastructure companies.
Major Sells: Reducing Amazon, Shopify, and Palantir
Amazon (AMZN): 30,050 shares, $7.6351 million
Shopify (SHOP): 43,517 shares, $7.5067 million
Palantir (PLTR): 29,957 shares, $6.0205 million
Block (XYZ): 40,368 shares, $3.0619 million
Personalis (PSNL): 146,911 shares, $2.3359 million
Toast (TOST): 53,344 shares, $1.5923 million
Amazon was the largest reduction by value on the day, involving multiple ETFs under ARK, extending recent selling activity. Overall, ARK's trading on the day focused on increasing holdings in innovative pharmaceuticals, biotechnology, and AI computing-related companies while cutting positions in some large technology, software, and fintech firms.
Comments